Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Safety and Efficacy of Recombinant Human Prolactin

This study has been completed.
Information provided by (Responsible Party):
Corrine Welt, Massachusetts General Hospital Identifier:
First received: February 20, 2007
Last updated: April 17, 2013
Last verified: April 2013
Medications used to increase breast milk production increase prolactin secretion, the main hormone of lactation. There are no FDA approved medications used to improve breast feeding, but metoclopramide is used off-label and can have intolerable side effects. We examined the biological activity and safety of recombinant human prolactin (r-hPRL) as a potential medication to augment lactation. In this study, the effect of r-hPRL on breast milk production in women who did not recently deliver a baby and its effect on the bones and menstrual cycle were tested.

Condition Intervention Phase
Drug: Recombinant Human Prolactin
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 2 Study of Recombinant Human Prolactin Efficacy and Safety

Resource links provided by NLM:

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • Galactorrhea [ Time Frame: 7 days ]
    Galactorrhea is breast milk production.

Secondary Outcome Measures:
  • Bone Turnover-deoxypyridinoline, N-telopeptide, Bone Specific Alkaline Phosphatase [ Time Frame: 7 days ]
  • Menstrual Cycle Length [ Time Frame: 28 days ]
  • Reproductive Hormones-LH, FSH, Estradiol [ Time Frame: 7 days ]

Enrollment: 21
Study Start Date: April 2002
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: recombinant human prolactin
Recombinant Human Prolactin 60 mcg/kg once daily subcutaneous injection
Drug: Recombinant Human Prolactin
Placebo Comparator: Placebo
Normal saline placebo subcutaneous injection
Drug: Recombinant Human Prolactin

Detailed Description:
There are no FDA approved medications in the U.S. to augment lactation. Metoclopramide is used off-label but can have intolerable side effects. We examined the biological activity and safety of recombinant human prolactin (r-hPRL) as preliminary data for its use to augment lactation. Healthy, non-postpartum women (n=21) with regular menstrual cycles underwent a 7 day randomized, double-blind, placebo-controlled trial of r-hPRL. Galactorrhea, markers of bone turnover, calcium homeostasis and gonadal function were measured and side effects recorded.

Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

Healthy Subjects will meet the following criteria:

  1. 18 to 40 years of age
  2. Normal weight (BMI 17 to £ 30 kg/m2)
  3. Good general health
  4. On no medications for at least 3 months before the study
  5. Regular menstrual cycles every 25-35 days with ovulation documented by a luteal phase progesterone level
  6. No evidence of androgen excess
  7. Normal TSH, prolactin and hematocrit
  8. No current interest in conception
  9. No history of osteoporosis
  10. No use of medications known to affect bone turnover
  11. No alcoholism
  12. No smoking
  13. No history of medical problems or treatment known to affect bone turnover.

Exclusion Criteria:

Subjects will be excluded for pregnancy or evidence of breast masses.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00438490

United States, Massachusetts
Corrine Welt
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Principal Investigator: Corrine K. Welt, MD Massachusetts General Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Corrine Welt, Associate Professor of Medicine, Massachusetts General Hospital Identifier: NCT00438490     History of Changes
Other Study ID Numbers: 2001-P-001057
Study First Received: February 20, 2007
Results First Received: February 5, 2013
Last Updated: April 17, 2013

Keywords provided by Massachusetts General Hospital:
bone turnover
menstrual cycle
Control Groups
Women processed this record on April 28, 2017